Polar Group

Polaris Group is a clinical-stage biopharmaceutical company primarily focused on developing metabolic therapies for cancer. Its lead candidate, ADI-PEG 20 (pegargiminase), is a first-in-class enzyme therapy that targets arginine-auxotrophic cancers by depleting systemic arginine levels. Beyond its core oncology pipeline, the company has expanded its technological capabilities through the acquisition of Nanotein Technologies, adding a high-throughput protein engineering platform. Polaris Group maintains a vertically integrated business model with internal R&D and cGMP manufacturing facilities located in the United States, Taiwan, and China. The company is publicly traded on the Taiwan Stock Exchange and continues to explore ADI-PEG 20 in combination with various chemotherapies and immunotherapies.